-
Most Recent
Search Results
240 results for COV
Hologic Stock Rides High on Strength of Coronavirus Testing
Hologic has carved out a meaningful niche in women’s health. But it’s coronavirus testing driving HOLX stock higher these days.
3 Stocks With the Largest 52-Week Losses
Although the stocks with largest 52-week losses are inherently risky, when the right ones are selected, they may also provide opportunities.
Upgrades This Week – BA, GIS, MSFT, NKE, PFE, GSK, MRK
Boeing (BA), General Mills (GIS), Microsoft (MSFT), and Nike (NKE) were among the widely-held stocks upgraded by Louis Navellier in his latest fundamental stock analysis…
Ocugen Stock Is a Risky Proposition Despite Its High Valuation
OCGN stock soared on a deal to commercialize Bharat Biotech’s Covaxin in the U.S., but the rollout comes with a lot of challenges.
3 Healthcare Acquisitions Google Should Consider
The best way for Google to make an even bigger splash in healthcare is through smart acquisitions like these 3 companies.
I Would Not Be Surprised If SRNE Stock Trades Below $5
SRNE stock is a purely speculative bet. The company has a deep pipeline of Covid-19 programs. But there is little progress or positive outcome.
There Is More To Pfizer Than The Covid Vaccine
Pfizer is a lot more than the covid vaccine. PFE stock has strong growth potential and is a great dividend stock for 2021.
Inovio Stock Poised for Growth as Preliminary Research Shows Promise
Vaccine trials are in progress, and although it isn’t the only player on the field, Inovio stock has a clear head-start on the competition.
It’s OK to Sell the News on Ocugen and Covaxin
OCGN stock jumped when Covaxin received WHO approval. But with two major obstacles in the way of U,S. approval, you should sell the news.
Novavax Is Looking More Like a Bet Worth Taking
NVAX stock fell behind other vaccine plays early in 2021, but it might not stay behind, There’s lots of evidence to suggest it could move…
iBio Stock Isn’t the Coronavirus Play Investors Want It to Be
Underscoring the volatility associated with companies purporting to be on the cusps of cures or treatments for international pandemics, IBIO has more than quadrupled just…
Rise with the Vaccine Tide and Buy Norwegian Cruise Line Stock
If you never considered NCLH stock as a “vaccine stock,” it’s time to reconsider your position as cruise-line investments are set to sail.
3 Reasons Ocugen Stock Should Maintain Its Upward Trajectory
OCGN stock has been counted out of the vaccine race many times, but there is plenty of room for optimism moving forward.
Sintx Joins List of Highly Speculative Covid-19 Plays
Sintx Technologies stock could be meaningful to investors as it’s one of several smaller companies that offers a way to play the pandemic.
Prepare for Another Pop to $15 With Ocugen Stock
Even while Ocugen changes up its strategy in the U.S., the company is pushing for approval elsewhere and OCGN stock can still move higher.
Why iBio Stock May Double or Triple in Value
IBIO stock is a potentially rewarding stock if customers use its manufacturing processes to scale up production of a Covid-19 vaccine.
10 – 10 of 240 results
